Oncology

Liver cancer
#Colorectal cancer #ETH Zurich #Liver cancer #Oncology #Tumour microenvironment (TME)

Study reveals how cancer cells metastasise to the liver

Researchers at ETH Zurich in Switzerland have uncovered how colorectal cancer cells colonise the liver. The findings, by Andreas Moor in the Department of Biosystems Science and Engineering and his team, will help to develop treatments with which they hope could hinder the metastatic process. Read More

#Cancer Research #News #Trending News

Cancer cells
#Cancer drug targets #Genetics / genomics #Institute of Cancer Research #Oncology #University of Cambridge #Wellcome Sanger Institute

Researchers identify potential new genetic target for cancer drugs

UK researchers have mapped the exact variants in a gene that dramatically increase a person’s risk of developing cancer, paving the way for targeted treatment across diverse populations. Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target… Read More

#Cancer Research #News #Trending News

#Cancer research #Cancer therapeutics #Haematology #Oncology

New DDW Highlights vodcast: 23 July 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   The chosen news stories this… Read More

#News

#Cancer research #Cancer therapeutics #Haematology #Oncology

New DDW Highlights podcast: 22 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The chosen news stories this week all feature therapies that could have significant… Read More

#News

Cancer cells
#Acute inflammatory conditions #Immuno-oncology #Oncodesign Precision Medicine #Oncology #Phase I trial

OPM tests first kinase inhibitor in clinic

Oncodesign Precision Medicine (OPM) has announced positive results of a Phase I trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV). OPM-101 is intended for the treatment of resistant and metastatic cancers. Read More

#Cancer Research #News

Cancer cell
#AstraZeneca #Breast cancer #EU #Gene mutation #MHRA #Oncology

Capivasertib approved for advanced breast cancer in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AstraZeneca’s capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. It is approved in cancers that have one or more abnormal PIK3CA, AKT1, or PTEN gene, and does… Read More

#News #Regulatory

Tumour microenvironment
#Cell and gene therapy #Cell therapy #Interview #Oncology #T cell receptor (TCR)

Unlocking T-cell receptor therapy for cancer

Keir Loiacono, CEO of BlueSphere Bio, discusses the goals of the company’s lead programme, the opportunities and potential of T-cell receptor (TCR) T cell therapies, and how to make oncology therapies tailored to individuals a reality. The goals of TCX-101 BlueSphere’s lead programme, TCX-101, includes two goals. The first is… Read More

#Cancer Research #Exclusive Content

#Cancer research #Cancer therapeutics #Haematology #Oncology

This week in drug discovery (15-19 July) 

News round-up for 15-19 July by DDW Senior Digital Content Editor Diana Spencer. The chosen news stories this week all feature therapies that could have significant impact on the future treatment of cancer, particularly haematological malignancies, but also solid tumours. The top stories:… Read More

#News

#CatalYm #Financing #Monoclonal antibodies #Oncology #Phase II trial

CatalYm raises $150m for cancer therapy visugromab

CatalYm has completed a $150 million Series D financing to support the Phase II development of its cancer therapy visugromab. The oversubscribed round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde Healthcare. Existing investors Jeito Capital, Brandon… Read More

#Business & Investment #Cancer Research #News

Natural killer cells
#Cell therapy #Imperial College London #Interview #Natural killer cells #NK:IO #Oncology

Natural born killers: University spinout turns NK cell therapy into business

Imperial College spinout NK:IO was awarded a £1.6m ($2m) Innovate UK New Cancer Therapeutics grant in 2023 to develop a pioneering NK cell therapy. Diana Spencer catches up with Co-Founder Mike Romanos to find out more. DS: How can NK cell therapy tackle the limitations of cancer immunotherapy? MR:  Cancer… Read More

#Cancer Research #Exclusive Content #Opinion #Start-up Zone

Cancer tumour
#4SC #Lymphoma #Oncology #Orphan drugs #Switzerland

Swiss Orphan Drug Status for cutaneous T-cell lymphoma drug

The Swiss Agency for Therapeutic Products (SwissMedic) has granted Orphan Drug Status (ODS) to 4SC’s Kinselby (resminostat) for the treatment of cutaneous T-cell lymphoma (CTCL). In Switzerland, ODS provides privileged status to drugs that show promise for the treatment of rare diseases and qualifies 4SC for benefits including fee reductions… Read More

#News #Regulatory

#Artificial intelligence (AI) #In vivo #Mouse models #Oncology #Oxford Drug Design

In vivo testing validates new approach to cancer treatment

In vivo testing has validated Oxford Drug Design’s potential first-in-class approach against multiple tumours, designed using its AI platform. The results of a 28-day mouse trial showed clear efficacy as well as dose response. The company’s approach is based on a novel target, leucyl-tRNA… Read More

#Cancer Research #News

#Breast cancer #Cancer research #DNA mutations #Epigenetics #Gene therapy #Oncology

New podcast shining a spotlight on cancer research developments

This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: The ‘dark matter’ behind cancer and Could this ‘Goldilocks’… Read More

#Cancer Research #News

Peptide
#Environmental impact #Oncology #Peptides #Sustainability #The University of Manchester

Discovery offers greener and more efficient peptide production

Scientists from the University of Manchester have uncovered a more efficient and sustainable way to make peptide-based medicines, showing promising effectiveness in combating cancers. Peptides are used in many medicines, as well as in vaccines and nanomaterials. However, making peptides in the lab is currently a… Read More

#Cancer Research #News

Pancreatic cancer
#Chemotherapy-resistance #Oncology #Pancreatic cancer #Stanford University #Treatment resistance

Study reveals potential target for new pancreatic cancer treatments

Researchers at Stanford University have revealed new insights related to pancreatic cancer’s resistance to chemotherapy. In a new paper, the scientists revealed that its resistance is related to both the physical stiffness of the tissue around the cancerous cells and the chemical makeup… Read More

#Cancer Research #Editor's Choice #News